You built a copay assistance program to help patients afford therapy. Most of your team still describes it that way internally. The problem is that by 2026, a meaningful share of every dollar manufacturers put into copay programs is captured by plan sponsors before it ever reaches the patient — and accumulators are the dominant mechanism.
Industry analysis from Drug Channels Institute consistently puts accumulator and maximizer adoption at roughly four in ten commercially insured lives. For specialty therapies, exposure is higher still.
Here is how the accumulator design works mechanically, and why the standard manufacturer response has stopped working.
A copay accumulator is a benefit-design choice. The plan excludes a drug — typically a specialty therapy — from counting toward the patient's annual deductible. The manufacturer's copay assistance pays first. The patient's deductible balance does not move while assistance is paying. When the manufacturer's copay program hits its annual benefit limit, the patient is suddenly exposed to full cost-sharing on the rest of the year.
From the patient's perspective, copay support disappears mid-year. From the manufacturer's perspective, the dollars set aside for patient affordability ended up funding plan-sponsor savings on the deductible side of the ledger.
The patient's out-of-pocket exposure either stays the same or gets worse. The manufacturer's program budget runs out faster than the actuarial model suggested. And next year's GTN forecast is built on the new, depleted baseline.
The first wave of industry defense against accumulators was retrospective. Vendors looked at paid claims, identified patterns consistent with accumulator behavior, and flagged them for the manufacturer weeks or months later. The funds were already gone.
The second wave was quarterly segmentation — running the claims dataset through a model to identify affected patients and adjust program design at the plan level. Better, but still behind the payer's move. By the time the segmentation runs, the patient has already been re-exposed.
The third wave — the one most manufacturers are now asking for by default — is real-time, first-fill identification. The goal isn't to measure how much was lost. The goal is to prevent the fund from leaving the program in the first place. That requires infrastructure that can identify exposure before the first claim adjudicates, segment with high accuracy, and protect the manufacturer's contribution at the point of sale.
A growing list of states has passed legislation requiring health plans to count manufacturer copay assistance toward patient deductibles. The list grows every year. The mechanics matter, though.
State laws apply to fully insured plans regulated by state insurance departments. They do not apply to self-insured ERISA plans, which cover the majority of commercial lives in the U.S. The plans most likely to use accumulator designs are exactly the plans state law cannot reach.
Federal action has been slower. As of 2026, the regulatory horizon for accumulators is closer to "uncertain" than "imminent."
That means the manufacturers whose programs survive intact through the next 24 months will be the ones who treat accumulator defense as a permanent capability, not a temporary workaround.
Every manufacturer running a specialty brand in 2026 is modeling GTN against a copay benefit budget that assumes a certain level of diversion. The manufacturers that outperform the category are the ones who shrink the diversion assumption — not the ones who build their model around it as a fixed cost.
That shift — from budgeting for diversion to preventing diversion — is the single largest near-term GTN lever most specialty brands have in front of them.
It requires the right kind of infrastructure. Specifically: infrastructure that identifies exposure before the first claim, protects funds in real time at the point of sale, and adapts as payer behavior evolves across the plan year. Every vendor claims to do this. Very few actually do.
Accumulators are not going to slow down. State-level regulation only addresses a fraction of the affected lives. Plan sponsor behavior is accelerating toward these designs because the economics are compelling for the plan.
The manufacturers whose economics survive the next 24 months will be the ones who treat accumulator defense as a real-time capability owned end to end — not a quarterly report.
Want to see what your specific program's accumulator exposure looks like? We can model it against your current program data, with no migration required. Request an exposure review.